Introduction
The precise anticancer mechanism of action of HDAC inhibitors is not yet well-defined and the rapid advancement of this class of compounds in clinical trials, at least in part, reflects the urgent need for new mechanism-based therapeutics for cancers that are not adequately treated by conventional therapies. The rationale for the clinical use of HDAC inhibitors is their ability to induce antiproliferative effects including induction of differentiation, cell cycle and growth arrest or in certain cases apoptosis, in numerous cancer cell-lines in culture and in vivo. [1] [2] [3] [4] These effects have been correlated with the accumulation of acetylated histones and consequent changes in gene expression. [1] [2] [3] [4] [5] Furthermore, the anticancer effects of HDAC inhibitors have been linked with their ability to alter the function of a growing list of non-histone substrates including, transcriptional factors such as p53, signal transduction mediators, and molecular chaperones. [1] [2] [3] [4] 6 Importantly, normal cells are more resistant to the cell-death inducing properties of HDAC inhibitors than transformed cells. 7 In addition to the potential use of HDAC inhibitors as stand alone therapeutics for cancer, there is excitement about the possibility of combining this class of drugs with other conventional chemotherapeutics and biological agents. [7] [8] [9] [10] For example, HDAC inhibitors have been identified to be additive or synergistic with a number of other therapeutics including anthracyclines 11, 12 tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL) 13, 14 and all-transretinoic acid. 15, 16 Also, HDAC inhibitors have been shown to be efficient radiation modifying agents and therefore, have been proposed as possible clinical radiation sensitizers or protectors. [17] [18] [19] Despite their relatively short history, HDAC inhibitors have realized both success and failure in clinical trials. For example, clinical trials in patients with pancreatic and lung cancer with the substituted benzamide derivative, CI-994 (acetyldinaline; Pfizer Global Research and Development, NY, USA) were abandoned due to inadequate efficacy, 20, 21 even though the compound showed very promising effects in preclinical studies, particularly in combination with other conventional chemotherapeutics. 22 In contrast, SAHA (also known as vorinostat and marketed as Zolinza; Merck & Co. Inc., NJ, USA), depsipeptide (also previously known as FK288 or FK901228 and given the generic name Romidepsin; Gloucester Pharmaceuticals Inc., MA, USA) and numerous other compounds are progressing in clinical trials. 2, 4, 7, 23 Both SAHA and depsipeptide have demonstrated anticancer effects at well-tolerated doses particularly in patients with hematologic malignancies. [24] [25] [26] Indeed, SAHA and depsipeptide have received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of advanced CTCL. In an important milestone, the FDA has recently accepted a New Drug Application for SAHA for the treatment of advanced CTCL and the compound has been granted priority review -an entitlement restricted for products that address an unmet medical requirement. Recent evidence from cell culture studies indicates that SAHA preferentially induces apoptosis in peripheral blood lymphocytes (PBL) from patients with CTCL with a high proportion of malignant T cells compared to PBL from healthy donors. 27 The therapeutic action of SAHA was shown to be due to accumulation of acetylated histones and consequent changes in the expression of proteins involved in the apoptotic pathway including p21 WAF1 bax, Stat6 and caspase-3. 27 Similarly, the clinical efficacy of depsipeptide has been previously correlated with histone acetylation in Sézary cells isolated from patients with CTCL. 25 
Distinct classes
The known human HDAC enzymes are grouped into classes on the basis of structural homology with three distinct yeast HDACs. 28, 29 Class I enzymes which include HDACs 1, 2, 3 and 8 are related to yeast reduced potassium dependency 3 (Rpd3) deacetylase. They are between 350 and 500 amino acids in length and are ubiquitously expressed and located primarily in the nucleus. 28, 29 Class II enzymes (about 1000 amino acids in length) are related to yeast histone deacetylase 1 (Hda1) and consist of HDACs 4, 5, 6, 9 and 10, 28,29 for a comprehensive review see article 2 ( Figure 1 ). These enzymes generally exhibit tissue-specific expression and shuttle between the cytoplasm and nucleus in response to cellular signals. 30 HDACs 6 and 10 contain two catalytic sites in tandem that are homologous with the Class II catalytic site and therefore, these enzymes are sometimes further divided into their own subclass (Class IIb).
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HDAC11 contains conserved residues that are shared by both class I and Class II enzymes and is usually classified as a class I enzyme however, recent phylogenetic studies indicate that it represents a separate class of HDACs (class IV). 29, 32 Like Class II enzymes, HDAC11 shows tissue-specific expression patterns. 33 Class III HDACs consists of the silencing information regulator 2 (Sir2) family of deacetylases which have a unique catalytic mechanism that requires the cofactor nicotinamide adenine dinucleotide (NAD þ ). 34 SAHA is a non-specific agent inhibiting the activity of class I, II and IV HDAC enzymes. 7 Depsipeptide has been shown to preferentially inhibit class I enzymes, however, it is still generally classified as a broadspectrum inhibitor because it does inhibit Class II enzymes, albeit, with lower potency. 35 Consistent with this classification is the recent microarray analysis which indicates that SAHA and depsipeptide regulate a highly overlapping gene set. 36 
Distinct functions
Although the precise cellular functions of the different HDAC enzymes are still poorly understood, evidence suggests that different members of the HDAC family have distinct functions. This was highlighted by recent studies in Drosophila melanogaster which indicate that individual HDACs have different biological roles. 37, 38 Importantly, with respect to cancer therapy it is emerging that class I HDAC enzymes are clinically relevant. 39, 40 However, this is still controversial and not absolute, as illustrated by the finding that inhibition of the Class II HDAC6 leads to acetylation and disruption of the chaperone function of heat-shock 90 protein in leukemic cells. 41 Nevertheless, the current evidence is swaying towards class I HDACs as the important cancer targets and this may call the therapeutic potential of broad-spectrum inhibitors such as SAHA and depsipeptide into question. It has been shown that targeted disruption of both HDAC1 alleles in mice results in embryonic lethality at very early stages of development mainly due to arrested cell growth. 39 This antiproliferative effect was correlated with decreased cyclin-associated kinase activities and elevated levels of the cyclin-dependent kinase inhibitors p21 WAF1 and p27 KIP139 Overall the knockout experiments highlight the essential, non-redundant role of HDAC1 in cell growth. 39 Similarly, studies using small interfering RNA (siRNA) to selectively knockdown class I HDAC1 and HDAC3 in HeLa cells provide further evidence that class I HDACs are essential for cancer cell proliferation and survival. 40 In contrast to knockdown of expression of class I HDACs, siRNA-mediated inhibition of the Class II HDACs, HDAC4 and HDAC7, did not result in either morphological changes or antiproliferative effects in cancer cells. 40 In addition, it has been demonstrated that knockdown of HDAC8 by RNA interference has antiproliferative effects in numerous cancer cell-lines providing evidence that this isoform may also be an important target for cancer therapy. 40 Furthermore, HDAC2 which is present in the same multicomponent nuclear complexes, such as the Sin3, NuRD and coREST as HDAC1, has also been identified to be important with respect to cell proliferation and survival. 42 It should be noted, however, that the findings from a recent study investigating HDAC activity in patients with chronic obstructive pulmonary disease (COPD), suggest that inhibition HDAC2 maybe contraindicated, at least in patients with COPD. 43, 44 Taken together, the emerging picture is that class I HDACs are important therapeutic targets for cancer. By considering the recent data with HDAC2 in COPD further research may reveal that for cancer therapy, targeting individual HDACs within class I may be more appropriate than targeting the entire class of enzymes.
Additionally, the findings from a recent study indicate that inhibition of class I but not Class II HDACs is important for sensitization of cancer cells to TRAIL-induced apoptosis, providing initial evidence that class I HDACs may also be more relevant when considering certain combination therapies. 45 An exception to this apparent rule may be combinations of HDAC inhibitors and ionizing radiation. 46 The findings from a particular study comparing the effect of inhibiting different classes of HDAC inhibitors on radiation sensitivity in cancer cells indicate that Trichostatin A (TSA), a non-specific class I and Class II inhibitor, is a more efficient radiation sensitizer than a HDAC which preferentially inhibits class I enzymes. 46 This is not unexpected as a specific role for HDAC4 (Class II HDAC) has been identified in the cellular DNA damage response pathway. It has been shown that in response to DNA damage, HDAC4 colocalizes with the key signalling protein, tumor suppressor p53-binding protein 1 (53BP1), in nuclear foci. 47 Furthermore, the data indicate that siRNA-mediated silencing of HDAC4 results in decreased levels of 53BP1 protein and enhanced sensitivity to the effects of ionizing radiation in Figure 1 Rendered models of Class I, II and IV histone deacetylase enzymes. Class I include HDAC1, 2, 3 and 8, Class II enzymes include HDAC4, 5, 6, 7, 9 and 10 and HDAC11 belongs to Class IV. Catalytic domains are illustrated in red and the degree of sequence homology between HDACs belonging to the same Class (Class I enzymes are compared against HDAC1 and Class II enzymes against HDAC10) is shown in the bottom right.
2 HDACs 6 and 10 contain two catalytic sites. Class III sirtuins are not illustrated.
cancer cells, highlighting the importance of HDAC4 in the DNA damage response. 47 Although we are only at the beginning of defining the functions of the different HDAC enzymes, on the basis of the above findings, it is tempting to forecast that future development and selection of HDAC inhibitors will depend on the context in which they will be used. In other words, it is foreseeable that ultimately HDAC inhibitors with varying specificity for individual HDAC-isoforms will be developed and the choice of which particular drug to use may be diseasedependent (given the different tissue expression patterns of individual HDACs and that inhibition of individual HDAC isoforms may be contraindicated in certain cases). Alternatively, the selection of a particular inhibitor may be related to its synergistic properties with other chemotherapeutics or radiotherapy.
Commercial potential
In the meantime, the potential to produce compounds with an improved therapeutic index for cancer therapy has driven the synthesis and evaluation of a number of small-molecule HDAC inhibitors that preferentially inhibit class I enzymes. In a relatively early study, the structure of trapoxin and the hydroxamic acid functional group were used as the basis to synthesize a series of cyclic hydroxamic acid-containing peptide (CHAP) analogs. 48 As CHAPs inhibited HDAC1 more efficiently than HDAC6 it was suggested that these hybrid analogs represent useful lead compounds for the development of isoform-specific HDAC inhibitors. 48 Similarly, synthetic hybrid inhibitors which preferentially inhibit class I HDAC have been developed using the hydroxamic acid functional group and the pyridyl moiety of the benzamide MS-275. 49 The two compounds that emerged, SK7041 and SK7068, preferentially inhibited class I HDACs. 49 Importantly, both compounds demonstrated potent anticancer effects in human gastric cancer cells and in vivo. 49 The most advanced selective class I HDAC inhibitor with respect to cancer therapy appears to be the benzamide MS-275 (Schering AG, Berlin, Germany). 50 This compound inhibits class I HDACs and is selective for HDAC1 (IC 50 0.3 mM) over HDAC3 (IC 50 8 mM) and HDAC8 (IC 50 4100 mM), but is less potent than the hydroxamic acidbased inhibitors which have activity in the nanomolar range. 51 MS-275 has already undergone phase I studies in patients with advanced and refractory solid tumors and lymphoma and is undergoing further clinical evaluation as a potential therapeutic for numerous malignancies. 50 In a relatively new development, another non-hydroxamate inhibitor, MGCD0103 (MethylGene Inc., Quebec, Canada) which specifically inhibits the class I HDACs, HDAC1, HDAC2, HDAC3 and the class VI HDAC11 with IC 50 values in the submicromolar range, has been developed and is undergoing clinical evaluation (USA patent no. 6897220). Other pharmaceutical companies including TopoTarget (København, Denmark) in collaboration with CuraGen (CT, USA), are also intensively developing isoform-specific HDAC inhibitors however, many of the details remain undisclosed.
Benefits to broad-spectrum inhibitors, past problem or future potential?
At this point, it should be reiterated that much information regarding the function of different HDAC enzymes is still in the private domain, and undisclosed compounds (which could be more potent and specific HDAC inhibitors than ones currently available) are already being developed for evaluation as cancer therapeutics. The perception is that isoform-specific HDAC inhibitors may offer a therapeutic advantage compared to the non-specific drugs. Specifically, the premise is that the greater specificity will correspond to modulation of a smaller number of disease-focussed genes and a reduced toxicity profile. Incidentally, initially HDAC inhibitors were thought to alter the expression of a relatively small number (2-10%) of genes, [52] [53] [54] however, recent microarray data (using improved analytical methods) indicates that the expression of at least 22% of genes is regulated over 16 h culture period by SAHA and depsipeptide. 36 Analysis indicated that both HDAC inhibitors altered the transcription of a largely overlapping set of genes involved in cell proliferation and apoptotic pathways. 36 This prompted the suggestion that the pleiotropic antiproliferative and apoptotic effects of SAHA and depsipeptide may be advantageous since suppression or loss of one particular pathway may not result in resistance to the compounds. 36 More generally, it may turn out that a broad-spectrum inhibitor such as SAHA or depsipeptide may be more beneficial than an isoform-specific drug which could inhibit cell growth or activate apoptosis via a more limited number of pathways. However, extensive research is required to substantiate such a hypothesis. In addition to the regulation of gene transcription, differences between broad-spectrum HDAC inhibitors and more specific molecules in altering the acetylation status of non-histone substrates involved in cell survival and apoptosis, will be important determinants of therapeutic efficacy. This area also remains largely unexplored.
Nevertheless, the findings from the clinical trials indicate that SAHA is well tolerated at the relevant doses and toxicities such as thrombocytopenia, neutropenia, fatigue, dehydration and anorexia are rapidly reversible upon discontinuation of the drug. 7, 55, 56 In general, depsipeptide has a similar toxicity profile to SAHA, 23 however, there is concern about cardiac toxicity with this compound, which requires further evaluation. [57] [58] [59] Furthermore, depsipeptide has been identified to be a substrate of the P-glycoprotein pump (Pgp) and multidrug resistance associated protein 1 and to induce the expression of Pgp, [60] [61] [62] [63] [64] which could limit its clinical utility. 65, 66 In the context of HDAC inhibitor-mediated toxicity, the recent correlation of the teratogenic effects of valproic acid with the inhibition of HDAC enzymes is important. 67 Similarly, TSA showed teratogenic effects in mice which were similar to those observed after VPA exposure, highlighting that toxicity with HDAC inhibitors could potentially become a greater concern as the drugs progress in the clinical setting. 68 Overall, as with most other types anticancer drugs there appears to be room for improvement with regards to toxicity and it will be critical to determine whether isoform-specific compounds will offer an advantage, compared to the classical broad-spectrum HDAC inhibitors.
Conclusion
In summary, emerging evidence is suggesting that HDAC inhibitors that specifically inhibit class I enzymes may offer a distinct therapeutic advantage compared to the classical broadspectrum inhibitors. However, the potential therapeutic advantage of isoform-specific HDAC inhibitors is still largely theoretical at this stage. Undoubtedly, further research relating to the function of the different HDAC enzymes will help clarify the issue. Ultimately, further development and thorough evaluation of isoform-specific small-molecule inhibitors will be the true measure of their clinical utility. For the moment, the classical HDAC inhibitors such as SAHA and depsipeptide are showing good therapeutic effects in clinical trials for cancer, and it remains to be seen whether their lack of specificity for HDAC isoforms is in fact a major disadvantage. Surely, if the broad-spectrum inhibitors continue to demonstrate a favorable therapeutic index in the clinical trials, their lifespan will be prolonged and they will ultimately be inducted as a new class of class of cancer therapeutics targeting the epigenome.
